Amgen (CHIX:AMGD) Debt-to-Revenue : 1.43 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AMGD Amgen Inc CHIX:AMGD
86 GF Score
Price €362.00
GF Value €336.84
! 5 Warning Signs
View Full Analysis

What is Amgen Debt-to-Revenue?

Amgen CHIX:AMGD 86 Debt-to-Revenue is 1.43 as of Jun. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 86/100 and a GF Value™ of €336.84. The stock has 5 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €4,726 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €45,014 Mil. Amgen's annualized Revenue for the quarter that ended in Jun. 2026 was €34,907 Mil. Amgen's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 was 1.42.

Amgen Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Amgen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Debt-to-Revenue Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 1.48 2.29 1.80 1.49

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 1.43 1.38 1.66 1.43

CHIX:AMGD vs GILD, PFE, BMY: Debt-to-Revenue Comparison

For the Drug Manufacturers - General subindustry, Amgen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen Debt-to-Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amgen's Debt-to-Revenue falls into.


CHIX:AMGD
86GF Score
Amgen Inc CHIX:AMGD
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Amgen's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3927.546 + 42704.27) / 31385.354
=1.49

Amgen's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4726.26 + 45013.612) / 34907.488
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 1.43 mean?
Amgen (CHIX:AMGD) has a Debt-to-Revenue of 1.43 as of Jun. 2026.
Is Amgen's Debt-to-Revenue too high?
Amgen's current Debt-to-Revenue is 1.43. Overall, Amgen has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Debt-to-Revenue compare to GILD and PFE?
Amgen's Debt-to-Revenue of 1.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Drug Manufacturers company?
A good Debt-to-Revenue depends on the Drug Manufacturers industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Amgen's current Debt-to-Revenue is 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (CHIX:AMGD) has a current Debt-to-Revenue of 1.43. The stock's GF Value™ is €336.84, compared to a current price of €362.00 — trading 7.5% above its estimated fair value. The current Debt-to-Revenue is 1.43. Amgen's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Debt-to-Revenue is 1.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €362.00 is trading 7.5% above its estimated GF Value™ of €336.84.

Key valuation signals for CHIX:AMGD:

  • Debt-to-Revenue: 1.43
  • GF Value™: €336.84 vs. price of €362.00 (7.5% above fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
86GF Score

Get the complete analysis for CHIX:AMGD

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€362.00
Price
€336.84
GF Value